Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib and Lenalidomide in MDS
NCT03359460Phase 1Completed
- Sponsor
- University of California, Davis
- Start
- Dec 2017
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ibrutinib in myelodysplastic syndrome (MDS), sponsored by University of California, Davis. Primary endpoint: Maximum tolerated dose at 28 days. Started Dec 2017; status: completed.
02
Drugs
ibrutinib
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT03359460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03359460.